142 related articles for article (PubMed ID: 17883595)
41. Expression of CD133, PAX2, ESA, and GPR30 in invasive ductal breast carcinomas.
Liu Q; Li JG; Zheng XY; Jin F; Dong HT
Chin Med J (Engl); 2009 Nov; 122(22):2763-9. PubMed ID: 19951611
[TBL] [Abstract][Full Text] [Related]
42. CD133 is indicative for a resistance phenotype but does not represent a prognostic marker for survival of non-small cell lung cancer patients.
Salnikov AV; Gladkich J; Moldenhauer G; Volm M; Mattern J; Herr I
Int J Cancer; 2010 Feb; 126(4):950-8. PubMed ID: 19676044
[TBL] [Abstract][Full Text] [Related]
43. Cucurbitacin I inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells.
Hsu HS; Huang PI; Chang YL; Tzao C; Chen YW; Shih HC; Hung SC; Chen YC; Tseng LM; Chiou SH
Cancer; 2011 Jul; 117(13):2970-85. PubMed ID: 21225866
[TBL] [Abstract][Full Text] [Related]
44. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells.
Chen KH; Hsu CC; Song WS; Huang CS; Tsai CC; Kuo CD; Hsu HS; Tsai TH; Tsai CY; Woung LC; Chiou SH; Lu KH; Chen YW
Childs Nerv Syst; 2010 Nov; 26(11):1605-12. PubMed ID: 20526717
[TBL] [Abstract][Full Text] [Related]
45. Radiation resistance and stem-like cells in brain tumors.
Hambardzumyan D; Squatrito M; Holland EC
Cancer Cell; 2006 Dec; 10(6):454-6. PubMed ID: 17157785
[TBL] [Abstract][Full Text] [Related]
46. Dueling models in head and neck tumor formation.
Umezawa A; Gorham JD
Lab Invest; 2010 Nov; 90(11):1546-8. PubMed ID: 21030945
[TBL] [Abstract][Full Text] [Related]
47. Clinical significance of stem cell marker CD133 expression in colorectal cancer.
Wang BB; Li ZJ; Zhang FF; Hou HT; Yu JK; Li F
Histol Histopathol; 2016 Mar; 31(3):299-306. PubMed ID: 26442717
[TBL] [Abstract][Full Text] [Related]
48. [The CD133 polyclonal antibody generation and cancer stem cells identification].
Tian JL; Cai PL; Xia XQ; Li FH; Wang DH; Chen MN
Sichuan Da Xue Xue Bao Yi Xue Ban; 2011 May; 42(3):422-6. PubMed ID: 21827013
[TBL] [Abstract][Full Text] [Related]
49. Increased expression of stem cell markers in malignant melanoma.
Klein WM; Wu BP; Zhao S; Wu H; Klein-Szanto AJ; Tahan SR
Mod Pathol; 2007 Jan; 20(1):102-7. PubMed ID: 17143262
[TBL] [Abstract][Full Text] [Related]
50. The Expression Status and Prognostic Value of Cancer Stem Cell Biomarker CD133 in Cutaneous Squamous Cell Carcinoma.
Xu R; Cai MY; Luo RZ; Tian X; Han JD; Chen MK
JAMA Dermatol; 2016 Mar; 152(3):305-11. PubMed ID: 26560495
[TBL] [Abstract][Full Text] [Related]
51. Characterization of a new human melanoma cell line with CD133 expression.
Gil-Benso R; Monteagudo C; Cerdá-Nicolás M; Callaghan RC; Pinto S; Martínez-Romero A; Pellín-Carcelén A; San-Miguel T; Cigudosa JC; López-Ginés C
Hum Cell; 2012 Jun; 25(2):61-7. PubMed ID: 22529031
[TBL] [Abstract][Full Text] [Related]
52. Blocking the NOTCH pathway can inhibit the growth of CD133-positive A549 cells and sensitize to chemotherapy.
Liu J; Mao Z; Huang J; Xie S; Liu T; Mao Z
Biochem Biophys Res Commun; 2014 Feb; 444(4):670-5. PubMed ID: 24502949
[TBL] [Abstract][Full Text] [Related]
53. CD133/CD15 defines distinct cell subpopulations with differential in vitro clonogenic activity and stem cell-related gene expression profile in in vitro propagated glioblastoma multiforme-derived cell line with a PNET-like component.
Kahlert UD; Bender NO; Maciaczyk D; Bogiel T; Bar EE; Eberhart CG; Nikkhah G; Maciaczyk J
Folia Neuropathol; 2012; 50(4):357-68. PubMed ID: 23319191
[TBL] [Abstract][Full Text] [Related]
54. More than 45% of A549 and H446 cells are cancer initiating cells: evidence from cloning and tumorigenic analyses.
Meng X; Wang X; Wang Y
Oncol Rep; 2009 Apr; 21(4):995-1000. PubMed ID: 19287999
[TBL] [Abstract][Full Text] [Related]
55. Differential clinical benefits of 5-fluorouracil-based adjuvant chemotherapy for patients with stage III colorectal cancer according to CD133 expression status.
Shikina A; Shinto E; Hashiguchi Y; Ueno H; Naito Y; Okamoto K; Kubo T; Fukazawa S; Yamamoto J; Hase K
Jpn J Clin Oncol; 2014 Jan; 44(1):42-8. PubMed ID: 24244031
[TBL] [Abstract][Full Text] [Related]
56. Prognostic value of cancer stem cell marker CD133 expression in pancreatic ductal adenocarcinoma (PDAC): a systematic review and meta-analysis.
Li X; Zhao H; Gu J; Zheng L
Int J Clin Exp Pathol; 2015; 8(10):12084-92. PubMed ID: 26722393
[TBL] [Abstract][Full Text] [Related]
57. CD133/Src axis mediates tumor initiating property and epithelial-mesenchymal transition of head and neck cancer.
Chen YS; Wu MJ; Huang CY; Lin SC; Chuang TH; Yu CC; Lo JF
PLoS One; 2011; 6(11):e28053. PubMed ID: 22140506
[TBL] [Abstract][Full Text] [Related]
58. [Expression of AC133 vs. CD34 in acute childhood leukemias].
Ebener U; Brinkmann A; Zotova V; Niegemann E; Wehner S
Klin Padiatr; 2000; 212(3):90-8. PubMed ID: 10916777
[TBL] [Abstract][Full Text] [Related]
59. The cancer stem cell marker CD133 interacts with plakoglobin and controls desmoglein-2 protein levels.
Koyama-Nasu R; Takahashi R; Yanagida S; Nasu-Nishimura Y; Oyama M; Kozuka-Hata H; Haruta R; Manabe E; Hoshino-Okubo A; Omi H; Yanaihara N; Okamoto A; Tanaka T; Akiyama T
PLoS One; 2013; 8(1):e53710. PubMed ID: 23326490
[TBL] [Abstract][Full Text] [Related]
60. Hypoxia promotes radioresistance of CD133-positive Hep-2 human laryngeal squamous carcinoma cells in vitro.
Wang M; Li X; Qu Y; Xu O; Sun Q
Int J Oncol; 2013 Jul; 43(1):131-40. PubMed ID: 23652853
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
